1. Annual report 2023
  2. Research
  3. DAP_CAT

DAP_CAT

Epidemiologic Research Group in Diabetes from Primary Health Care

The research team is made up of professionals from various disciplines and we focus research on the study of diabetes and its complications, both in the hospital and primary care settings, demonstrating a great ability to generate projects and publications in the last years The group's main lines of research are two: a) Complications of diabetes: atherosclerosis and microvascular disease, as the main causes of morbidity and mortality b) Epidemiology of diabetes: research in primary care and use of large databases. In recent years, the group has developed projects using the SIDIAP database in different aspects of diabetes in real medical practice (real-world evidence). The group is a pioneer at State level in this area, and has active collaborations with international groups. In the last 5 years the group has published 309 articles of which 160 are in Q1 (52%) and 42 in D1 (14%). The average Impact factor of the articles is 7.06 and they have 9625 citations.

Group projects

R+D+I PROJECTS FUNDED IN COMPETITIVE CALLS FROM ADMINISTRATIONS OR PUBLIC AND PRIVATE ENTITIES

  • Premi Trajectòria Investigadora AP ICS 2022. ICS - Institut Català de la Salut. -2023. IP: Josep Franch Nadal.

  • PERIS - Personal suport grup DAP_CAT. (SLT028/23/000124). Generalitat Catalunya. Departament de Salut. 2023-2025. IP: Josep Franch Nadal.

  • La Retinopatia Diabètica com a predictor de la morbilitat cardiovascular i la mortalitat en pacients amb Diabetis tipus 2. ICS - Institut Català de la Salut. 2021-2025. IP: Joan Francesc Barrot de la Puente.

  • Grup de recerca epidemiológica en Diabetis des de l'Atenció Primària de Catalunya (DAP.cat). (SENIOR-19/2). ICS - Institut Català de la Salut. 2020. IP: Josep Franch Nadal.

  • GRCS Grup Recerca Cures Salut. (2013-027). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2013IP:Carolina Lapena Estella.

  • Anàlisi de l´atenció a la Diabetis i les seves complicacions cròniques a Catalunya mitjançant la base de dades SIDIAP. (INTENS-19/12). ICS - Institut Català de la Salut. 2020-2023. IP: José Manuel Mata Cases.

  • Relación epidemiológica entre Diabetes y Tuberculosis. Estudio longitudinal sobre la asociación entre las dos enfermedades en un distrito de alta prevalencia de Tuberculosis. (PREDOC_ECO-19/2). ICS - Institut Català de la Salut. 2020-2024. IP: Violeta Antonio Arques.

  • Perspectiva de gènere i factors de risc cardiovascular en diabetis. ICS - Institut Català de la Salut. 2022-2024. IP: Anna Mª Ramírez Morros.

CLINICAL STUDIES

  • Prevalencia, incidencia, factores de riesgo y complicaciones relacionadas con la disfunción eréctil entre las personas con diabetes mellitus tipo 2 en la base de datos de atención primaria SIDIAP-Estudio epiDEDM2cat. 2023-2026. IP: Bogdan Vlacho Vlacho.

  • International diabetes federation diabetes atlas data from Catalonian population database. ICS - Institut Català de la Salut. 2020-2023. IP: Dídac Mauricio Puente.

  • ImpactT2D: una estrategia genómica para implementar medicina de precisión en la diabetes tipo 2. (PMP21/00102). Instituto de Salud Carlos III. 2021 IP: Josep Franch Nadal.

  • Impacto de la diabetes y la obesidad en la infección por SARS-CoV-2: Identificación de factores pronóstico y creación de un score predictivo basado en técnicas de inteligencia artificial. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2021-2023. IP: Josep Franch Nadal.

  • una de las ondas epidémicas?. (PI21/01318). Instituto de Salud Carlos III. 2021 IP: José Manuel Mata Cases.

  • Global and country-specific rates and trends in the incidence of diagnosed type 2 diabetes (GLOBALDIAB). Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2022-2024. IP: José Manuel Mata Cases.

  • Gestational diabetes and complications among pregnant women attended in primary care sexual and reproductive health services in Catalonia. Primary Care Diabetes Europe. 2021-2024.PI21/0 IP: Josep Franch Nadal.

  • Evolución de la enfermedad renal en las personas con DM2 según los valores iniciales de filtrado glomerular y el tratamiento antidiabético. Estudio epiERDM2.cat. (PI22/00989). Instituto de Salud Carlos III. 2023-2025. IP: Joan-Antoni Vallès Callol.

  • Evolución de control metabólico de la diabetes tipo 2 en atención primaria de Cataluña. ICS - Institut Català de la Salut. 2021 IP: José Manuel Mata Cases.

  • Estudio sobre los resultados de la adición de una sulfonilurea, un iDPP4 o un iSGLT2 como segundo antidiabético en pacientes con DM2 en tratamiento con metformina e insuficiente control glucémico. Estudio eControl Metf+. AstraZeneca Farmacéutica Spain, S.A. 2017-2023. IP: Josep Franch Nadal.

  • Estudio de la epidemiología y la evolución de la Enfermedad Renal Crónica en las personas con DM2 respecto a la población no diabética. Estudio epiERC_DM2.cat. 2023IP:Josep Franch Nadal.

  • Epidemiología de SARS-CoV-2 en personas con obesidad y/o diabetes mellitus en Cataluña - Estudio epiCOVID19DMO. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2020-2023. IP: Dídac Mauricio Puente.

  • Epidemiología de la hipertrigliceridemia grave y su relación con la incidencia de pancreatitis aguda y enfermedad cardiovascular en Cataluña. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2020-2023. IP: Emilio Ortega Martínez de Victoria.

  • ContRol de la diabEteS tipo 2 En tIempoS de pandemia COVID-19 en centros de aTención primaria. Estudio RESIST. Redgedaps, s.l. 2021 IP: Josep Franch Nadal.

  • Caracterización de subgrupos de diabetes mellitus tipo 2 al diagnóstico: un paso necesario hacia la medicina de precisión en diabetes, estudio COPERNICAN. (PI21/01163). Instituto de Salud Carlos III 2021-2024. IP: Dídac Mauricio Puente.

  • Aportacions de la genètica a la caracterització de una cohort de Medicina Personalitzada de Precisió en el moment del debut de la diabetis. (SLT/21/000030). Generalitat Catalunya.Departament de Salut. 2022IP:Josep Franch Nadal.

  • A single-centre, open-label study testing the safety and performance of the Glyconics-SX System in assessment of glycated nail keratin, compared with standardised glycated haemoglobin (HbA1c) assay, in individuals with or without type 2 diabetes in Catalonia (Spain). GLYCONICS LTD. 2022-2023. IP: Francesc Xavier Cos Claramunt.

  • A Real-World Database Study of Canagliflozin Utilization in Type 1 Diabetes Patients Over Time among European Countries. Janssen Research & Development, LLC. 2021IP:Josep Franch Nadal.

  • A pivotal multi-centre, open-label, two-part clinical investigation confirming the safety and accuracy of the Glyconics-DS in assessment of glycated nail keratin in individuals with unknown diabetes status and performance evaluation of the Glyconics SW package delivering the dichotomised results in Catalonia (Spain). (DAP-NIRDM-2023-04). GLYCONICS LTD. 2023-2026. IP: Francesc Xavier Cos Claramunt.

  • A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs (EXCEED). IQVIA LTD. 2020 IP: Josep Franch Nadal.

  • Estudi descriptiu de les característiques clíniques i l'abordatge terapèutic dels factors de risc cardiovascular al debut de la diabetis tipus 2 (DM2) en funció del sexe en una cohort d'atenció primària a Catalunya. 2022-2025. IP: Anna Mª Ramírez Morros.

  • Epidemiologia de diabetis gestacional i d'alteracions glucèmiques en el postpart a Catalunya. Estudi epiDMGCAT. Institut d'Investigació en Atenció Primària Jordi Gol i Gurina (IDIAPJGol). 2020-2023. IP: Berta Soldevila Madorell.

Group publications

JOURNAL PUBLICATIONS

  • Falip M, González FJL, Martín Herranz I, Merino Bohórquez V, Montoya J, Gómez Serranillos IR et al. Value contribution of cenobamate for the treatment of Focal-Onset Seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective Multi-Criteria Decision Analysis (MCDA). Epilepsy Behav. 2023;145109350-109350. PMID:37480633.

  • Ortega E, Vlacho B, Treserres RP, Mata Cases M, Altes A, Mauricio D et al. Severe hypertriglyceridemia prevalence at a primary care setting in Catalonia, Spain. J. Clin. Lipidol. 2023;17(6):777-787. PMID:37741728.

  • Seidu S, Cos X, Topsever P. Self-rated knowledge and competence regarding the management of chronic kidney disease in primary care: A cross-sectional European survey of primary care professionals. Prim Care Diabetes. 2023;17(1):19-26. PMID:36513582.

  • Pennells L, Kaptoge S, Ostergaard HB, Read SH, Carinci F, Franch Nadal J et al. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur. Heart J. 2023;44(28):2544-PMID:37247330.

  • Simó R, Franch Nadal J, Vlacho B, Real J, Amado E, Flores J et al. Rapid Reduction of HbA1c and Early Worsening of Diabetic Retinopathy: A Real-world Population-Based Study in Subjects With Type 2 Diabetes. Diabetes Care. 2023;46(9):1633-1639. PMID:37428631.

  • Bundo M, Vlacho B, Llussa J, Bobe I, Aivar M, Ciria C et al. Prediction of outcomes in subjects with type 2 diabetes and diabetic foot ulcers in Catalonian primary care centers: a multicenter observational study. J. Foot Ankle Res. 2023;16(1):8-8. PMID:36849888.

  • Mauricio D, Vlacho B, Ortega E, Cos Claramunt X, Mata Cases M, Real J et al. Outcome of COVID-19 infection in people with diabetes mellitus or obesity in the primary care setting in Catalonia, Spain: A retrospective cohort study of the initial three waves. Prim Care Diabetes. 2023;17(1):12-18. PMID:36528549.

  • Kong A, Cos X. Management of people with prediabetes and the implementation of diabetes prevention programme. Prim Care Diabetes. 2023;17(4):285-286. PMID:37394313.

  • Rojo López MI, Bermúdez López M, Castro E, Farràs C, Torres G, Pamplona R et al. Low adherence to the Mediterranean diet is associated with increased prevalence and number of atherosclerotic plaques in the ILERVAS cohort. Atherosclerosis. 2023;380117191-117191. PMID:37586219.

  • Mollo A, Vlacho B, Gratacos M, Mata Cases M, Rubinat E, Berenguera A et al. Impact of a multicomponent healthcare intervention on glycaemic control in subjects with poorly controlled type 2 diabetes: The INTEGRA study. Diabetes Obes. Metab. 2023;25(4):1045-1055. PMID:36546592.

  • Rodriguez Calvo R, Granado Casas M, de Oca A, Julian MT, Domingo M, Codina P et al. Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus. Antioxidants. 2023;12(3):PMID:36978893.

  • Gimenez Perez G, Vinals C, Mata Cases M, Vlacho B, Real J, Franch Nadal J et al. Epidemiology of the first-ever cardiovascular event in people with type 1 diabetes: a retrospective cohort population-based study in Catalonia. Cardiovasc. Diabetol. 2023;22(1):179-179. PMID:37452416.

  • Ortiz Zúñiga A, Simó Servat O, Amigó J, Sánchez M, Morer C, Franch Nadal J et al. Efficacy of Insulin Titration Driven by SMS in Improving Glycemic Control in People with Type 2 Diabetes. J Clin Med. 2023;12(19):PMID:37835008.

  • Romero Aroca P, Verges R, Pascual Fontanilles J, Valls A, Franch J, Barrot J et al. Effect of Lipids on Diabetic Retinopathy in a Large Cohort of Diabetic Patients after 10 Years of Follow-Up. J Clin Med. 2023;12(20):PMID:37892811.

  • Mauricio D, Gratacòs M, Franch Nadal J. Diabetic microvascular disease in non-classical beds: the hidden impact beyond the retina, the kidney, and the peripheral nerves. Cardiovasc. Diabetol. 2023;22(1):314-314. PMID:37968679.

  • Montero E, Bujaldón R, Montanya E, Calle Pascual AL, Rojo Martínez G, Castaño L et al. Cross-sectional association between severe periodontitis and diabetes mellitus: A nation-wide cohort study. J. Clin. Periodontol. 2023;51(4):368-379. PMID:38140803.

  • Sanjurjo L, Castelblanco E, Julve J, Villalmanzo N, Téllez E, Ramirez Morros A et al. Contribution of Elevated Glucose and Oxidized LDL to Macrophage Inflammation: A Role for PRAS40/Akt-Dependent Shedding of Soluble CD14. Antioxidants. 2023;12(5):PMID:37237950.

  • Giannella A, Castelblanco E, Zambon CF, Basso D, Hernandez M, Ortega E et al. Circulating Small Noncoding RNA Profiling as a Potential Biomarker of Atherosclerotic Plaque Composition in Type 1 Diabetes. Diabetes Care. 2023;46(3):551-560. PMID:36577032.

  • Julve J, Genua I, Quifer Rada P, Yanes O, Barranco Altirriba M, Hernández M et al. Circulating metabolomic and lipidomic changes in subjects with new-onset type 1 diabetes after optimization of glycemic control. Diabetes Res. Clin. Pract. 2023;197110578-110578. PMID:36804334.

  • Alcubierre N, Granado Casas M, Bogdanov P, Hernandez C, Ramos H, Castelblanco E et al. Caffeine and the Risk of Diabetic Retinopathy in Type 2 Diabetes Mellitus: Findings from Clinical and Experimental Studies. Nutrients. 2023;15(5):PMID:36904168.

  • Valdés S, Doulatram Gamgaram V, Maldonado Araque C, Garcia Escobar E, Garcia Serrano S, Oualla Bachiri W et al. Association between exposure to air pollution and blood lipids in the general population of Spain. Eur. J. Clin. Invest. 2023;54(2):PMID:37795744.

  • Vlacho B, Mata Cases M, Fernandez Camins B, Liebana LR, Barrot de la Puente J, Franch Nadal J. Adherence to the therapeutic guidelines recommendations among the people with type 2 diabetes mellitus and obesity, frailty, or recent diagnosis, attended in primary health care centers in Spain: A cross-sectional study. Front Med (Lausanne). 2023;101138956-1138956. PMID:37035300.

  • Julian MT, Ballesta S, Pera G, de Oca A, Soldevila B, Caballeria L et al. Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study. Front. Endocrinol. 2023;131051958-1051958. PMID:36714592.

  • Mollo A, Vlacho B, Gratacos M, Mata Cases M, Rubinat E, Osso AB et al. A multicomponent health care intervention is associated with improved glycaemic control in subjects with poorly controlled type 2 diabetes compared with routine care: The INTEGRA study. Diabetes Obes. Metab. 2023;25(12):3549-3559. PMID:37608473.

  • Mora N, Fina F, Méndez Boo L, Cantenys R, Benítez M, Moreno N et al. "Decline and uneven recovery from 7 common long-term conditions managed in the Catalan primary care after two pandemic years: an observational retrospective population-based study using primary care electronic health records". BMC Prim. Care. 2023;24(1):9-9. PMID:36641483.

  • Hernández Teixidó C, López Simarro F, Arranz Martínez E, Escobar Lavado FJ, Miravet Jiménez S. Vulnerabilidad y determinantes sociales en diabetes. Med. Fam.-SEMERGEN. 2023;49(8):102044-102044. PMID:37481793.

  • Viadé J, Nicolás M, Bundó M, Sirvent M, Riera C, Sabriá M. A novel assessment, diagnostic and treatment system for diabetic foot. J. Foot Ankle Res. 2023;16(1):84-84. PMID:38001471.

PROCEEDING PAPERS

  • Simó R, Franch Nadal J, Vlacho B, Real J, Amado E, Mata Cases M et al. Rapid Reduction of HbA1c and EarlyWorsening of Diabetic Retinopathy: A Real-world Population-based Study in Subjects with Type 2 Diabetes. Eur. J. Ophthalmol. 2023;33(1):5-6.

  • Simo R, Franch Nadal J, Vlacho B, Real J, Amado E, Flores J et al. Rapid reduction of HbA1c and early worsening of diabetic retinopathy: a real-world population-based study in subjects with type 2 diabetes. Diabetologia. 2023;66(SUPPL 1):460-460.

  • Puigpinós R, Lapena C, Masip J, González T. Qualitative evaluation of an art intervention to reduce loneliness in the older people: ARTGRAN. Gac. Sanit. 2023;3794-94.

TECHNICAL DOCUMENTS

  • Mundet TuduriX, CegriF, SalvadorB, Segura AnducasA, Cobo GuerreroS, Vinyoles BargallóE et al. Consens català sobre atenció a la malaltia renal crònica (Consenso catalán sobre atención a la enfermedad renal crónica; Catalan consensus on chronic kidney disease care). 2023;

Anar a l'inici